Englese Thomas
Known title: CHIEF COMMERCIAL OFFICERCIK: 0001825799
Englese Thomas's purchase track record
Englese Thomas has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/14/2021 | ELUT | $28K | -26.2% | -1.5% | -19.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ELUT | ▼ Sell | Open Market | 289 | $1K | 3/9/2023 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 937 | $0 | 3/8/2023 | View on chart |
| ELUT | ▼ Sell | Tax Withholding | 4,728 | $35K | 9/8/2022 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 15,390 | — | 9/8/2022 | View on chart |
| ELUT | ▼ Sell | Open Market | 276 | — | 3/10/2022 | View on chart |
| ELUT | ▲ Buy | Option Exercise | 938 | $0 | 3/8/2022 | View on chart |
| ELUT | ▲ Buy | Open Market | 4,580 | $28K | 12/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.